Conclusion: This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
PubMed 34302978 ↗Tirzepatide
Also known as Mounjaro, Zepbound
The short answer. Most people who report on Tirzepatide say it helped (75% of 287). It is most often used for weight loss: 94% of 206 reports say that improved. It is well studied — 214 meta-analyses on PubMed. The most common complaint is nausea.
From 428 mentions in total — the rest didn't say how it went and aren't counted.
What Tirzepatide does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 214 meta-analyses on PubMed ↗ · 132 randomized trials ↗
Conclusion: Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
PubMed 38613667 ↗Conclusion: Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.
PubMed 39719170 ↗Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.
PubMed 40186344 ↗296 human trials on ClinicalTrials.gov test Tirzepatide — 91 completed, 97 recruiting now. See all on ClinicalTrials.gov ↗
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes · Obesity, Overweight · 2026
- Tirzepatide for Obesity and Meth Use Disorder · Obesity, Methamphetamine Use Disorder · 2026
- Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes · Non-diabetec Obesity, Obesity (Disorder) · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance…”
21 recalls of products named for Tirzepatide. Most recent:
- 2026-03-11 · Class II: Lack of Assurance of Sterility record ↗
- 2025-11-05 · Class II: Lack of Assurance of Sterility record ↗
- 2025-10-15 · Class II: Lack of Assurance of Sterility record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
160,663 adverse-event reports mention Tirzepatide. Most often reported:
- Incorrect dose administered · 29,672
- Nausea · 17,092
- Injection site pain · 13,906
- Diarrhoea · 10,006
- Extra dose administered · 9,608
- Off label use · 8,941
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Tirzepatide C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗
NIH has funded 8 research projects with Tirzepatide in the title, $7,874,070 in total (2024–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Tirzepatide injection ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“Tirzepatide works so well! Do some research in the r/peptides subreddit and the r/tirzepatide subreddit. It's the most effective thing I've ever seen for appetite suppressant.”
“I’m currently on tirzepatide 7.5mg (midway dose). Stacking sema because tirz isn’t helping it’s serious insomnia and sexual side effects.”
“The Tirz was amazing and I dropped to a maintenance dose after I hit 195. When I stopped all peptides for two weeks prior to surgery, the Tirz didnt do anything when I restarted.”
“mounjaro has been the best. I lost like 15 pounds in two months on this thing.”
Tirzepatide compared
Other options for weight loss
Sources
- User reports: 428 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate